US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Elite Pharmaceuticals, Inc.

0.5230

+0.00310.60%

Volume:1.22M

Turnover:627.55K

Market Cap:561.91M

PE:-41.66

High:0.5244

Open:0.5134

Low:0.5050

Close:0.5199

52wk High:0.8194

52wk Low:0.2700

Shares:1.07B

Float Shares:831.02M

Volume Ratio:2.27

T/O Rate:0.15%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0126

EPS(LYR):-0.0046

ROE:25.58%

ROA:26.63%

PB:9.12

PE(LYR):-113.35

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Elite Pharmaceuticals Reports 92% Revenue Increase for Fiscal Q2 2026

Elite Pharmaceuticals Receives FDA Approval for Generic Requip XL

Elite Pharmaceuticals Inc. to Release Second Quarter 2026 Financial Results

Elite Pharmaceuticals EVP Operations Douglas Plassche Reports Disposal of Common Shares

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ELTP"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ELTP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ELTP\",,,,,undefined,":{"symbol":"ELTP","market":"US","secType":"STK","nameCN":"Elite Pharmaceuticals, Inc.","latestPrice":0.523,"timestamp":1764968400000,"preClose":0.5199,"halted":0,"volume":1219832,"delay":15,"floatShares":831015098,"shares":1074396422,"eps":-0.012554,"marketStatus":"Market Closed","change":0.0031,"latestTime":"12-05 16:00:00 EST Delay","open":0.5134,"high":0.5244,"low":0.505,"amount":627546.30773,"amplitude":0.037315,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.012554,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"OTCQB","adjPreClose":0.5199,"volumeRatio":2.2745456339319103},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ELTP\",,,,,undefined,":{"symbol":"ELTP","floatShares":831015098,"roa":"26.63%","roe":"25.58%","lyrEps":-0.004614,"volumeRatio":2.2745456339319103,"shares":1074396422,"dividePrice":0,"high":0.5244,"amplitude":0.037315,"preClose":0.5199,"low":0.505,"week52Low":0.27,"pbRate":"9.12","psRate":"4.57","week52High":0.8194,"institutionHeld":0,"latestPrice":0.523,"eps":-0.012554,"divideRate":0,"volume":1219832,"delay":15,"ttmEps":-0.012554,"open":0.5134,"prevYearClose":0.5411,"prevWeekClose":0.5321,"prevMonthClose":0.5321,"prevQuarterClose":0.6401,"fiveDayClose":0.5321,"twentyDayClose":0.601,"sixtyDayClose":0.6872},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ELTP\",params:#limit:5,,,undefined,":[{"date":"2025-11-14","symbol":"ELTP","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1763110800000,"name":null,"time":"","dateTimestamp":1763096400000,"actualEps":null},{"date":"2025-08-14","symbol":"ELTP","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755158400000,"name":null,"time":"","dateTimestamp":1755144000000,"actualEps":null},{"date":"2025-06-30","symbol":"ELTP","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1751313600000,"name":null,"time":"Post Market","dateTimestamp":1751256000000,"actualEps":null},{"market":"US","date":"2025-02-13","symbol":"ELTP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1739422800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-14","symbol":"ELTP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ELTP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ELTP\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ELTP\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2583988684","title":"Elite Pharmaceuticals Reports 92% Revenue Increase for Fiscal Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2583988684","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583988684?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:19","pubTimestamp":1763155198,"startTime":"0","endTime":"0","summary":"Elite Pharmaceuticals, Inc. reported consolidated revenues of $36.3 million for the second quarter of fiscal year 2026 ended September 30, 2025, representing an increase of $17.4 million, or approximately 92%, compared to the same period in the prior fiscal year. Income from operations was $8.2 million, an increase of $4.7 million, or approximately 136%, compared to the comparable period of the prior year. The increase in revenue and income from operations was primarily attributed to sales of Elite's lisdexamfetamine products, which were launched after the prior year's comparable period, as well as overall growth in Elite label product lines. The company will host a conference call to discuss these results and recent business developments.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be int","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL3kc9dQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELTP"],"gpt_icon":0},{"id":"2582373018","title":"Elite Pharmaceuticals Receives FDA Approval for Generic Requip XL","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373018","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582373018?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:02","pubTimestamp":1762948976,"startTime":"0","endTime":"0","summary":"Elite Pharmaceuticals Inc. announced that it has received approval from the US Food and Drug Administration  for its Abbreviated New Drug Application  for a generic version of Requip XL  in 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg strengths. The product, intended for the treatment of Parkinson's disease symptoms, will be marketed under the Elite Laboratories, Inc. label. According to IQVIA, the branded product and its equivalents recorded US sales of $10 million for the twelve months ending September 2025. The approval is exclusive to Elite Pharmaceuticals Inc.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elite Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile  on November 12, 2025, and is sol","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDLbjJWzB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1201861249.SGD","BK4530","LU0130517989.USD","LU0528227936.USD","ELTP","LU0198837287.USD","LU0882574055.USD","LU1261432733.SGD","BK4588","LU1791710400.SGD","LU1989764748.USD","LU0648001328.SGD","LU0648000940.SGD","LU1201861165.SGD","BK4121","LU0477156953.USD","LU0130103400.USD","BK4585","LU0130102774.USD","BK4007","LU0980610538.SGD","IQV","LU0477156797.USD","LU0130518102.USD","LU1791710582.SGD","LU1989764664.SGD"],"gpt_icon":0},{"id":"2582948873","title":"Elite Pharmaceuticals Inc. to Release Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2582948873","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582948873?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:04","pubTimestamp":1762776251,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elite Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile  on November 10, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL3h6bK0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELTP"],"gpt_icon":0},{"id":"2572630464","title":"Elite Pharmaceuticals EVP Operations Douglas Plassche Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2572630464","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572630464?lang=en_us&edition=fundamental","pubTime":"2025-10-04 09:59","pubTimestamp":1759543162,"startTime":"0","endTime":"0","summary":"Douglas Plassche, EVP Operations at Elite Pharmaceuticals Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elite Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251004:nNDL3wFp83:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELTP"],"gpt_icon":0}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":13,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ELTP\",params:#limit:6,delay:false,,,undefined,":[]}}